Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/16—Inorganic salts, minerals or trace elements
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/428—Thiazoles condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7016—Disaccharides, e.g. lactose, lactulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to a composition and method for preventing or treating fatty pancreas, ameliorating pancreatic lesions caused by fatty pancreas, diabetes or other related disorders.
• the pancreas is an exocrine and endocrine organ in the human body.
• the exocrine part includes acinar cells, which can secrete a variety of digestive enzymes.
• the endocrine part includes islets, which can secrete insulin and other hormones, which play an important role in maintaining blood sugar levels. Fat accumulation in the pancreas may affect pancreatic function, further causing pancreatic lesions, diabetes, or other related conditions.
• diabetes is a disease of abnormal glucose metabolism.
• non-insulin-dependent or adult-type also known as type II diabetes
• insulin-dependent or infant-type also known as type I. diabetes.
• type 2 diabetes usually occurs in adults and is highly associated with obesity, and can be controlled through appropriate exercise, diet, and medications; type I diabetes is more common in children and adolescents, and the patient's body does not produce enough Insulin must be sustained by injection of insulin.
• the present invention provides for the efficacy of one or more compounds having reduced pancreatic fat content, preventing or treating fatty pancreas, ameliorating pancreatic lesions caused by fatty pancreas, diabetes or other related disorders in an individual selected from the group consisting of: Poncirin, isovitexin, eriodictyol, ergosterol, ⁇ -myrcene, hyperoside, catechin ((+ )-catechin), palmitic acid ethyl ester, galangin, Morin, sciadopitysin, didymin, gossypin, luteolin-7-Glucoside, dihydroquercetin ((+)-taxifolin), citric acid (trans-cinnamic acid), xysmin, linarin, homoorientin, xylitol, rhinofolium ( Luteolin), swertiamarin, sodium lauryl sulfate, menthol, sucralose, mannitol, crospovid
• the present invention provides the compound or a derivative, metabolite or decomposition product thereof for use in preparing an individual to reduce pancreatic fat content, prevent or treat fatty pancreas, improve pancreatic lesions caused by fat pancreas, diabetes or other Use of a composition of a related disorder.
• the present invention also proposes to reduce pancreatic fat content, prevent or treat fatty pancreas, improve pancreatic lesions caused by fat pancreas, diabetes or other by administering the compound or a derivative, metabolite or decomposition product thereof in an individual in need thereof. Methods of related disorders.
• the compound is selected from the group consisting of menthol, mannitol, eriodictyol, sucralose, and any combination thereof.
• the compound is (1) menthol, mannitol, and eriodictyol, (2) mannitol, and eriodictyol. Combination, (3) combination of mannitol and sucralose, (4) combination of eriodictyol and sucralose, (5) menthol and mannitol a combination of (mannitol), or (6) a combination of eriodictyol, mannitol, and sucralose.
• pancreatic lesions or related conditions include alcoholic fatty pancreatic disease and nonalcoholic fatty pancreatic disease, wherein alcoholic fatty pancreatic diseases include, but are not limited to, alcoholic fatty steatopancreatitis and alcoholic Pancreatitis (alcoholic Pancreatitis), as well as nonalcoholic fatty pancreatic diseases including, but not limited to, nonalcoholic fatty steatopancreatitis, pancreatic lipomatosis, pancreatic steatosis, fatty pancreas ), lipomatous pseudohypertrophy of pancreas, fatty replacement of pancreas, and fatty infiltration of pancreas (Nat. Rev. Gastroenterol. Hepatol. 8, 169–177 (2011) ); World J Gastroenterol. 2006 Dec 14; 12(46)
• the compounds of the invention may be formulated into pharmaceuticals, food supplements or health foods.
• the present invention provides a composition comprising a combination of any two or more compounds selected from the group consisting of: poncirin, isovitexin, Eriodictyol, ergosterol, myrcene, hyperoside, catechin ((+)-catechin), palmitic acid ethyl (palmitic acid ethyl) Ester), galangin, morin, sciadopitysin, didymin, gossypin, luteolin-7-glucoside (luteolin- 7-Glucoside), (+)-taxifolin, trans-cinnamic acid, diosmin, linarin, homoorientin, wood Xylitol, luteolin, swertiamarin, sodium lauryl sulfate, menthol, sucralose, mannitol , crospovidone, sorbitol, saccharin, glycerin, sodium benzoate Oxidized iron red, pregelatinized starch
• compositions of the present invention comprise a combination of any two or more compounds selected from the group consisting of: menthol, mannitol, eriodictyol ) and sucralose.
• compositions of the present invention comprise a combination selected from the group consisting of: (1) a combination of menthol, mannitol, and eriodictyol, ( 2) Combination of mannitol and eriodictyol, (3) combination of mannitol and sucralose, (4) eriodictyol and sucralose Combination, (5) a combination of menthol and mannitol, or (6) a combination of eriodictyol, mannitol, and sucralose.
• the present invention also provides for the efficacy of one or more compounds to modulate pancreatic function, particularly to reduce impaired pancreatic function and symptoms of diabetes due to accumulation of fat, for example, against insulin resistance and hypoglycemia.
• One or more of the compounds described herein as set forth herein include the compound itself, as well as derivatives, metabolites, and decomposition products thereof.
• Such derivatives include, but are not limited to, structural isomers, complexes, salts, esters, chelates or any precursors which can be used to produce the compounds described herein in vivo.
• the present invention discloses that one or more of the compounds described above have the effect of reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related conditions in an individual. Accordingly, the present invention provides the use of a compound as described in a composition for reducing pancreatic fat content, preventing or treating fatty pancreas, ameliorating pancreatic lesions caused by fatty pancreas, diabetes or other related disorders. The invention also provides a method of reducing pancreatic fat content, preventing or treating fatty pancreas, ameliorating pancreatic lesions caused by fatty pancreas, diabetes or other related disorders, comprising administering to a subject in need thereof an effective amount of said compound. The present invention also provides a composition for reducing pancreatic fat content, preventing or treating fatty pancreas, improving pancreatic lesions caused by fatty pancreas, diabetes or other related disorders in an individual.
• One or more of the compounds as described above include the compound itself, derivatives, metabolites, and decomposition products thereof.
• the foregoing derivatives include, but are not limited to, structural isomers, complexes, salts, esters A class, chelate or any precursor that can produce a compound described herein in vivo.
• pancreatic fat content refers to the amount of fat accumulated in the pancreas in an individual, including lipids in a broad sense, such as triglyceride (TG) and cholesterol.
• reducing pancreatic fat content generally means lowering the abnormal pancreatic fat content in an individual to a normal level or closer to a normal level, and may also refer to comparing the same individual before and after taking the drug, wherein the individual is after taking the agent.
• the body's pancreatic fat content is lower than the body's pancreatic fat content before taking the drug.
• the normal level of pancreatic fat content can be assessed by measuring and collecting pancreatic fat content of normal individuals in a population.
• pancreatic fat content For example, for a group of people, such as the normal level of pancreatic fat content is 3% of the weight of the pancreas, when the fat weight in the pancreas exceeds 5% of the weight of the pancreas, it is an abnormal accumulation of fat, then "reduced pancreatic fat content.” It can mean that the abnormal pancreatic fat content in the individual is reduced to 3% of the weight of the pancreas (the above pancreatic fat content is a relative value and is exemplified, which may vary due to individual ethnic groups and other factors).
• "fatty pancreas” may refer to a condition in which the pancreatic fat content in an individual is above normal levels. Standard methods of analysis can be used to assess pancreatic fat content, including but not limited to, ultrasound analysis, magnetic resonance imaging MRI, magnetic resonance spectrum MRS, computed tomography CT, pancreatic pathology.
• the compound includes commonly used excipients and bioflavonoids, which are readily available in the field (such as commercially available), can be used to reduce pancreatic fat content, prevent or treat fat pancreas, and improve fat.
• pancreatic lesions or conditions including abnormalities due to accumulation of pancreatic fat include alcoholic fatty pancreas and nonalcoholic fatty pancreas.
• treatment refers to the administration or administration of a composition comprising one or more active agents to an individual having a disease, a symptom or condition of the disease, or a disease progression, the purpose of which is to treat, cure, relieve, Alleviate, alter, remedy, improve, improve, or affect the disease, the symptoms or conditions of the disease, the disability caused by the disease, or the deterioration of the disease.
• prevention refers to a preventive or preventive measure for a disease, a symptom or condition of a disease, including but not limited to, the application or administration of one or more active agents to a possible unrecognized condition.
• the words "individual” or “individual” as used herein include human or non-human animals, such as companionship. Animals (such as dogs, cats, etc.), farm animals (such as cattle, sheep, pigs, horses, etc.), or experimental animals (such as rats, mice, guinea pigs, etc.).
• the term "effective amount” refers to the amount of active ingredient that produces a desired biological or medical effect on an individual being treated, for example, reducing the pancreatic fat content of an individual, preventing or treating fatty pancreas, and improving fatty pancreas. Caused by pancreatic lesions, diabetes or other related conditions.
• a therapeutically effective amount of the active ingredient according to the invention may be formulated into a pharmaceutical composition in a suitable form with apharmaceutically acceptable carrier.
• the term "pharmaceutically acceptable” means that the carrier is compatible with the active ingredient of the composition (without affecting the action of the active ingredient), and is preferably stable to the active ingredient and is safe for the individual to be treated .
• the carrier can be a diluent, carrier, excipient, or vehicle of the active ingredient.
• suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, poly Vinyl pyrrolidone, cellulose, sterile water, syrup, and methylcellulose.
• the composition may additionally comprise a lubricant such as talc, magnesium stearate, and mineral oil; a wetting agent; an emulsifier and a suspending agent; a preservative such as methyl and propyl hydroxybenzoate; a sweetener; Agents, etc.
• a lubricant such as talc, magnesium stearate, and mineral oil
• a wetting agent such as talc, magnesium stearate, and mineral oil
• an emulsifier and a suspending agent such as methyl and propyl hydroxybenzoate
• a preservative such as methyl and propyl hydroxybenzoate
• the composition may be in any form, for example, as a tablet, a pill, a powder, a lozenge, a sachet, a cachet, an elixir, a suspension, an emulsion, a solution, a syrup, a soft and hard gelatin capsule. , suppositories, sterile injections, and packaging powders.
• compositions of the invention may be delivered via any physiologically acceptable route, for example, orally, parenterally (e.g., intramuscular, intravenous, subcutaneous, and intraperitoneal), transdermal, suppository, and intranasal methods, and the like.
• parenterally e.g., intramuscular, intravenous, subcutaneous, and intraperitoneal
• transdermal e.g., transdermal
• suppository e.g., transdermal
• intranasal methods e.g., transdermal
• intranasal methods e.g., transdermal, suppository, and intranasal methods, and the like.
• parenteral administration it is preferred to use a sterile aqueous solution which may contain other substances such as salts or glucose sufficient to render the solution isotonic with blood.
• the aqueous solution is suitably buffered (preferably having a pH of 3 to 9) depending on the requirements.
• the present invention also contemplates that one or more compounds have the effect of modulating pancreatic function, particularly reducing impaired pancreatic function due to accumulation of fat, for example, symptoms of diabetes.
• the efficacy of the compounds of the invention includes combating insulin resistance and lowering blood glucose.
• Standard analytical methods can be used to assess impaired pancreatic function and sugar Symptoms of urinary diseases, including but not limited to, blood glucose levels, glycosylated hemoglobin (HbA1C), glucose tolerance test (GTT), blood insulin concentration, homeostasis model assessment of insulin resistance , HOMA-IR), tumor necrosis factor-alpha analysis, interleukin-6 (IL-6) analysis, interleukin-1beta, IL- 1 ⁇ ) analysis and the like.
• HbA1C glycosylated hemoglobin
• GTT glucose tolerance test
• HOMA-IR tumor necrosis factor-alpha analysis
• IL-6 interleukin-6
• IL-1beta interleukin-1beta
• mice For the test animals B6 mice, only 4 rats in each group were pre-tested, and only 12 rats in each group were confirmed. Male mice were housed in the normal light and dark cycle (lighting period from 7:00 am to 7:00 pm, the rest is dark period), temperature 23 ⁇ 2 ° C, relative humidity 55 ⁇ 15% in the animal room, weight 18 ⁇ 23g . After being purchased into the National Defense Animal Center by Lesco Biotech Co., Ltd. (Taipei), the animal experiment was carried out in accordance with the National Health Center experimental guidelines. First, feed 3-5g per day with normal feed, keep 1-2 weeks to observe the state of health, water is unlimited supply, and the body weight is recorded once a week.
• test animals were randomly divided into a blank control group (Blank), a high-fat control group (HFD), a positive control group (PS), and a test group.
• the blank control group was given normal feed; the high-fat control group was given high-fat diet; the positive control group was given high-fat diet and tube fed silymarin (5 mg/kg/day) (Iranian Journal of Pharmaceutical Research (2016), 15(3): 493-500; Life Sciences 75 (2004) 2167-2180; and Pharm Biol. 2016 Jul 8: 1-6); and the test group is for the administration of high fat feed and individual tube test components.
• the blank control group was given normal feed for 12 weeks, and the high-fat control group, the positive control group and the experimental group were High-fat diet for 12 weeks. After 8 weeks of feeding, the blank control group and the high-fat control group were given deionized water once a day; the control group was given a silymarin once a day; the test group was given a test compound once a day for 4 weeks.
• Serum triglyceride (TG) and total cholesterol (TCHO, TC) were measured by an automatic blood biochemical analyzer.
• pancreatic biochemical function blood glucose analysis (GLU, blood glucose analysis)
• Blood glucose analysis was performed using a Roche ACCU-CHEK Active blood glucose machine. One day before the blood collection, the mice were fasted overnight. Insert the code card of the blood glucose test paper into the blood glucose meter, and then insert the blood glucose test paper. The blood drop pattern appears on the standby device. A blood drop is taken from the cheek vein of the mouse to the blood glucose machine test paper to record the blood glucose meter. Blood glucose data.
• pancreatic biochemical function intraperitoneal glucose tolerance test (IPGTT)
• mice were moved to a clean cage for fasting overnight, where there was no food or feces in the feeding funnel or bottom of the clean cage, ensuring that the animals had access to drinking water at all times.
• the body weight of the mice was measured, and the volume of the glucose solution required for intraperitoneal (IP) injection was calculated (concentration: 250 mg/mL, 2 g glucose/mouse body weight, kg, required volume ( ⁇ l) was 8 x body weight (g)) .
• IP intraperitoneal
• the mice were removed, and an appropriate amount of glucose solution was intraperitoneally injected into the mice, and the injection time was recorded.
• blood was taken from the tail of the mouse, blood glucose concentration was measured, and blood glucose analysis was performed using a Roche ACCU-CHEK Active blood glucose machine.
• mice were fasted for blood collection at the end of the test (12 weeks) and were performed according to the instructions of the mouse ultrasensitive insulin ELISA kit (ALPCO).
• ALPCO mouse ultrasensitive insulin ELISA kit
• mice were fasted for blood collection at the end of the test (12 weeks), and blood glucose and insulin concentrations were measured and calculated according to the following formula:
• pancreas specimens were taken by laparotomy, and the pancreas weight/body weight ratio was compared after weighing. In addition, the remaining pancreas was cryopreserved for detection of triglyceride and total cholesterol in the pancreas.
• test results are calculated by the single factor analysis of variance (ANOVA) test to determine whether there is a statistically significant difference, using the Statistical Package of the Social Science program (Version 13, SPSS Inc.) software package to calculate; then use the post hoc test least significant difference method to make multiple comparisons to confirm significant differences between ethnic groups; significant differences in ethnic averages are p ⁇ 0.05.
• SD standard deviation
• ANOVA single factor analysis of variance
• the other animals were given high-fat diet.
• the animals in each group were given different treatments for 4 weeks, among which, the blank control group and high fat.
• the control group was given deionized water
• the control group was given silymarin
• the test group was given different test compounds, including puerarin, phloridzin, eriodicty, sucralose, mannitol, saccharin, orange peel, menthol, or A combination of test compounds.
• puerarin phloridzin, eriodicty, sucralose, mannitol, saccharin, orange peel, menthol, or A combination of test compounds.
• test compounds are safe and sound.
• test compound has the effect of reducing pancreatic lipids
• Table 1 Test compounds reduce pancreatic lipids in animals (during 4 weeks of dosing).
• eriodictyol, mannitol, saccharin, sucralose, orange peel, puerarin, menthol, phloridzin can significantly reduce total cholesterol in the pancreas, a decrease of about 28% -51%; in particular, saccharin treatment At 4 weeks, the excellent effect was achieved, which reduced the total cholesterol content of the pancreas by about 51% (p ⁇ 0.005).
• a combination of menthol and mannitol or a combination of menthol, mannitol and eriodictin, wherein the dose of each component is maintained at the same or each dose as used alone.
• a similar or better reduction in triglyceride effect can be achieved when the dosage of the other ingredients is lower than the dosage used alone (for example, about three-thirds of the dose used alone).
• a combination of specific test compound combinations can reduce the amount of drug, but maintain similar or better efficacy, resulting in a synergistic effect.
• test compound has the function of regulating pancreatic function and treating diabetes symptoms
• Test compound can regulate pancreatic function and reduce pancreatic function damage in animals (during 4 weeks of administration)
• Test compound can regulate pancreatic function and reduce pancreatic function damage in animals (during 4 weeks of administration)
• This experiment detects whether the test compound can regulate pancreatic function and reduce the damage of pancreatic function in animals, especially for carbohydrate metabolism.
• pancreatic metabolism function of the pancreas of the high fat diet mice was impaired (GLU, IPGTT, fasting insulin concentration, HOMA-IR value increased).
• Sucralose, menthol, mannitol, and saccharin can significantly reduce GLU when administered a single test compound; eriodictyol, sucralose, menthol, mannitol, saccharin, and puerarin can significantly reduce sugar Tolerance; phlorizin, eriodicty, sucralose, menthol, mannitol, saccharin, and puerarin significantly reduced fasting insulin concentrations and insulin resistance.
• test compound has the effect of reducing triglyceride in plasma
• Table 3 Test compounds reduce triglycerides in plasma of animals (during 4 weeks of dosing)
• the combination of menthol and mannitol or the combination of eriodictin and sucralose can significantly reduce triglycerides in plasma when a combination of two test compounds is administered.
• menthol mannitol
• eriodictol effectively lowers triglycerides in plasma at low doses when a combination of three test compounds is administered.
• the compound provided by the invention can reduce pancreatic fat content and improve related diseases in individuals, and the compounds belong to low molecular natural plant phenolic compounds, which are widely present in fruits and vegetables, grains, rhizomes, flowers, teas and red wines, and are tested by animals. Confirmed safe and flawless, with the potential to develop pancreatic fat, prevent or treat fatty pancreas, improve pancreatic lesions caused by fat and pancreas, diabetes or other related conditions, regulate pancreatic function, and especially improve insulin resistance. .

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Mycology (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Inorganic Chemistry (AREA)
• Botany (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Orthopedics, Nursing, And Contraception (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (3)

Family

ID=58717399

Family Applications (1)

Country Status (12)

Families Citing this family (2)

Citations (5)

Family Cites Families (7)

• 2016
  • 2016-11-21 US US15/777,385 patent/US20180325840A1/en active Pending
  • 2016-11-21 FI FIEP16865806.0T patent/FI3378481T3/fi active
  • 2016-11-21 WO PCT/CN2016/106607 patent/WO2017084631A1/zh not_active Ceased
  • 2016-11-21 JP JP2018526113A patent/JP6914256B2/ja active Active
  • 2016-11-21 ES ES16865806T patent/ES2949047T3/es active Active
  • 2016-11-21 CN CN202411541590.9A patent/CN119424472A/zh active Pending
  • 2016-11-21 HU HUE16865806A patent/HUE062181T2/hu unknown
  • 2016-11-21 PL PL16865806.0T patent/PL3378481T3/pl unknown
  • 2016-11-21 PT PT168658060T patent/PT3378481T/pt unknown
  • 2016-11-21 CN CN202411541425.3A patent/CN119524140A/zh active Pending
  • 2016-11-21 DK DK16865806.0T patent/DK3378481T3/da active
  • 2016-11-21 CN CN201680067605.XA patent/CN109715170A/zh active Pending
  • 2016-11-21 TW TW105138160A patent/TWI797068B/zh active
  • 2016-11-21 EP EP16865806.0A patent/EP3378481B1/en active Active

Patent Citations (5)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events